Search

Your search keyword '"Naïve human immunodeficiency virus-infected patients"' showing total 2 results
Start Over Descriptor "Naïve human immunodeficiency virus-infected patients"
2 results on '"Naïve human immunodeficiency virus-infected patients"'

1. Is Antiretroviral Two-Drug Regimen the New Standard for HIV Treatment in Naive Patients?

Author

Dupont, Emilie and Yombi, Jean Cyr

Subjects
INTEGRASE inhibitors, VIRAL load, PROTEASE inhibitors, HIV, LIFE expectancy
Abstract

The use of a combination antiretroviral therapy (cART) has changed dramatically the prognosis and the life expectancy of people living with HIV. The current treatment guidelines continue the convention of preferred cART based on combining a dual nucleoside reverse-transcriptase inhibitor (NRTI) backbone with a third "anchor" agent, such as a ritonavir (r)- or cobicistat (c)-boosted protease inhibitor (PI), a non-NRTI (NNRTI), or an integrase inhibitor (INI) boosted or unboosted. However, due to toxicities of NRTIs, sparing NRTI regimen has been studied for a long time with moderate success due to low efficacy (especially in patients with high viral load and low CD4) compare to standard triple therapy. New strategy with lamivudine (3TC) plus a boosted PI or INI showed promise results and indicated that modern two-drug regimens might now, in fact, become a reliable treatment for HIV-infected naïve patients. This article discusses recent data from dual therapy studies in naïve HIV-infected patients and the challenges behind this strategy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

2. Is Antiretroviral Two-Drug Regimen the New Standard for HIV Treatment in Naive Patients?

Author

Jean Cyr Yombi, Emilie Dupont, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine interne générale, UCL - (MGD) Pathologie infectieuse, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Subjects
Oncology, Cart, Dual therapy, medicine.medical_specialty, Integrase inhibitor, HIV Infections, immune system diseases, Antiretroviral Therapy, Highly Active, Internal medicine, medicine, Humans, Pharmacology (medical), Protease inhibitor (pharmacology), HIV Integrase Inhibitors, 3TC, business.industry, Cobicistat, virus diseases, Lamivudine, Standard of Care, HIV Protease Inhibitors, General Medicine, Viral Load, Naïve human immunodeficiency virus-infected patients, Antiretroviral therapy, CD4 Lymphocyte Count, Regimen, Treatment Outcome, Infectious Diseases, Protease inhibitor, Anti-Retroviral Agents, Practice Guidelines as Topic, Reverse Transcriptase Inhibitors, Ritonavir, business, Viral load, medicine.drug
Abstract

The use of a combination antiretroviral therapy (cART) has changed dramatically the prognosis and the life expectancy of people living with HIV. The current treatment guidelines continue the convention of preferred cART based on combining a dual nucleoside reverse-transcriptase inhibitor (NRTI) backbone with a third "anchor" agent, such as a ritonavir (r)- or cobicistat (c)-boosted protease inhibitor (PI), a non-NRTI (NNRTI), or an integrase inhibitor (INI) boosted or unboosted. However, due to toxicities of NRTIs, sparing NRTI regimen has been studied for a long time with moderate success due to low efficacy (especially in patients with high viral load and low CD4) compare to standard triple therapy. New strategy with lamivudine (3TC) plus a boosted PI or INI showed promise results and indicated that modern two-drug regimens might now, in fact, become a reliable treatment for HIV-infected naïve patients. This article discusses recent data from dual therapy studies in naïve HIV-infected patients and the challenges behind this strategy.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results